Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P58012
UPID:
FOXL2_HUMAN
Alternative names:
-
Alternative UPACC:
P58012; Q4ZGJ3
Background:
Forkhead box protein L2 (FOXL2) plays a pivotal role in ovary differentiation and maintenance, acting as a transcriptional regulator. It is instrumental in repressing the genetic program for somatic testis determination, thereby preventing ovary-to-testis trans-differentiation. FOXL2's functions extend to apoptotic activity in ovarian cells and regulation of genes critical for reproductive health.
Therapeutic significance:
Mutations in FOXL2 are linked to Blepharophimosis, Ptosis, and Epicanthus Inversus Syndrome (BPES), a condition with eyelid malformations and, in some cases, female infertility due to premature ovarian failure. Understanding FOXL2's role could lead to novel treatments for BPES and premature ovarian failure, highlighting its therapeutic significance.